New generation stents coated with medicines, results of clinical tria

The advent of drug-eluting stents (DCTs) in the early 21st century has dramatically changed the strategy for revascularization in coronary artery disease. Target stenosis and large Dermatological coronary interventions with the use of DKS compared with conventional metal stents, due to a significant reduction in the frequency of re-interventions of cardiac complications of coronary heart disease (CHD) the strategy of revascularization quickly dominated in patients with. Despite the progress made using first generation DQS (Cypher, Taxus)the frequency of severe cardiac complications (mortality, myocardial infarction, re-injury) remained high for 5 years and approached 20% [1]. The main problems of the first generation DQS era were manifested in late and very late stent thrombosis, as well as late resolution of vascular perforation. First generation DQS These "shortcomings" forced manufacturers to create a new generation of DQS.Больше информации об этом исходном текстеЧтобы получить дополнительную информацию, введите исходный текст Отправить отзывБоковые панели